Ken PowellKen has over 35 years’ experience in the pharmaceutical and biotechnology sectors. He is an expert virologist and has been involved in the development of multiple drugs including antiviral compounds for Herpes, HIV, Hepatitis C and RSV. He is also the Chair of ReViral, a company developing antiviral drugs to treat Respiratory Syncytial Virus (RSV) infection. Previously Ken was the Executive Chairman of Q-Chip, a company developing novel formulations of drugs. He was also the Founder and CEO of Arrow Therapeutics, a specialised antiviral drug discovery company acquired by Astra-Zeneca in 2007. Ken has held a professorship with UCL and was a senior pharmaceutical executive with the Wellcome Foundation. He has a PhD in Virology from the University of Birmingham.